Signed license agreement on new class molecules for cancer treatment –

Signed license agreement

A new class of peptides for cancer treatment developed at UiT-The Arctic University is via Norinnova licensed to the company Lytix Biopharma AS. 

The peptides are developed by inventors Johann Eksteen, John Sigurd Mjøen Svendsen and Øystein Rekdal. 

Actors from UiT-The Arctic University, Norinnova , Lytix, Norce, Oslo University Hospital and Gustave Roussy in Paris have participated in a verification project of the peptides partly funded by the Research Council of Norway and the Cancer Society.

The license agreement gives Lytix an exclusive right to further develop and commercialize this new class of molecules, helping to build up the Lytix platform and pipeline of new candidates. One of the peptides has shown particularly promising results for cancer treatment in veterinary medicine, and Lytix has already started a strategic partnership with the company Aurelius Therapeutics to ensure progress with this molecule.    

Nordlys has interviewed the CEO of Lytix Biopharma Øystein Rekdal, read the case here